Recursion to Host Public L(earnings) Call on February 27
20 févr. 2024 07h59 HE
|
Recursion Pharmaceuticals
SALT LAKE CITY, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide...
Altitude Lab Startups Raise Over $120M in Capital
24 janv. 2024 09h00 HE
|
Recursion Pharmaceuticals
SALT LAKE CITY, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Altitude Lab today announced that its incubating startups raised over $120M in early-stage funding since commencing operations in 2020. Altitude Lab...
Recursion Unveils LOWE Drug Discovery Software at the J.P. Morgan Healthcare Conference
08 janv. 2024 10h59 HE
|
Recursion Pharmaceuticals
SAN FRANCISCO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today presented a demonstration...
Recursion to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8
03 janv. 2024 08h00 HE
|
Recursion Pharmaceuticals
SALT LAKE CITY, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that Chris...
Recursion and Enamine to Generate and Design Enriched Compound Libraries for Global Drug Discovery Industry
20 déc. 2023 07h59 HE
|
Recursion Pharmaceuticals
KYIV, Ukraine and SALT LAKE CITY, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today...
Bayer and Recursion Focus Research Collaboration on Oncology
09 nov. 2023 09h41 HE
|
Recursion Pharmaceuticals
Berlin, Germany and Salt Lake City, USA, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Bayer and US-based Recursion Pharmaceuticals, Inc., a clinical stage TechBio company decoding biology to industrialize drug...
Recursion Provides Business Updates and Reports Third Quarter 2023 Financial Results
09 nov. 2023 07h58 HE
|
Recursion Pharmaceuticals
Entered into a collaboration with Tempus giving Recursion access to over 20 petabytes of multimodal oncology data for the purpose of training causal AI models together with Recursion’s proprietary...
Recursion to Participate in Upcoming Investor Conference
02 nov. 2023 08h05 HE
|
Recursion Pharmaceuticals
SALT LAKE CITY, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its...
Recursion to Participate in Upcoming Investor Conferences
05 sept. 2023 16h30 HE
|
Recursion Pharmaceuticals
SALT LAKE CITY, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its...
Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection
05 sept. 2023 07h59 HE
|
Recursion Pharmaceuticals
SALT LAKE CITY, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has...